AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the appointment of Anthony Quinn, M.B Ch.B, Ph.D., FRCP to its Board of Directors. Dr. Quinn most recently served as executive vice president, chief medical officer and head of research & development at Synageva Biopharma Corp. until its acquisition by Alexion Pharmaceuticals in 2015.
